

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 16, 2025

Rh4

RRID:CVCL_5916

Type: Cell Line

Proper Citation

(RRID:CVCL_5916)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_5916

Proper Citation: (RRID:CVCL_5916)

Sex: Female

Defining Citation: [PMID:7536457](#), [PMID:8275086](#), [PMID:9823299](#), [PMID:19235922](#), [PMID:23578105](#), [PMID:23665679](#), [PMID:23882450](#), [PMID:25806826](#), [PMID:25894527](#), [PMID:36768928](#)

Comments: Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Deep exome analysis., Omics: Cell surface proteome., Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Name: Rh4

Synonyms: RH4, Rh-4, SJRH-4, SJRH4, SJ-RH4, SJ-Rh 4

Cross References: BTO:BTO_0005381, EFO:EFO_0022574, cancercellines:CVCL_5916, Cell_Model_Passport:SIDM01349, Cosmic:687959, Cosmic:801756, Cosmic:1037295, Cosmic:1048108, Cosmic:1097744, Cosmic:1104559, Cosmic:1108738, Cosmic:1309336, Cosmic:2820088, DepMap:ACH-001765, GEO:GSM219756, GEO:GSM1012758, Lonza:486, PRIDE:PXD000589, PRIDE:PXD039480, Wikidata:Q54950344

ID: CVCL_5916

Record Creation Time: 20250131T202441+0000

Record Last Update: 20250131T204336+0000

Ratings and Alerts

No rating or validation information has been found for Rh4.

No alerts have been found for Rh4.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Danielli SG, et al. (2024) Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer. *Molecular cancer therapeutics*, 23(6), 864.

Danielli SG, et al. (2023) Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance. *Science advances*, 9(6), eade9238.

Milton CI, et al. (2022) FGF7-FGFR2 autocrine signaling increases growth and chemoresistance of fusion-positive rhabdomyosarcomas. *Molecular oncology*, 16(6), 1272.

Polyanskaya SA, et al. (2022) SCP4-STK35/PDIK1L complex is a dual phospho-catalytic signaling dependency in acute myeloid leukemia. *Cell reports*, 38(2), 110233.

Malone CF, et al. (2021) Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer. *Cancer discovery*, 11(9), 2282.

Gryder BE, et al. (2020) Measurement of differential chromatin interactions with absolute quantification of architecture (AQuA-HiChIP). *Nature protocols*, 15(3), 1209.

Marques JG, et al. (2020) NuRD subunit CHD4 regulates super-enhancer accessibility in rhabdomyosarcoma and represents a general tumor dependency. *eLife*, 9.

Sanna L, et al. (2019) "Verteporfin exhibits anti-proliferative activity in embryonal and alveolar rhabdomyosarcoma cell lines". *Chemico-biological interactions*, 312, 108813.